Libor Holík

Recent publications · Crossref

5 total works indexed

1. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

   · 2015 · cited 6,935x

2. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

   · 2018 · cited 2,955x

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

   · 2019 · cited 2,784x

4. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

   · 2019 · cited 2,530x

5. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

   · 2017 · cited 2,069x

via Crossref · CC0